According to Zacks, “Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars – first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patients tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients TSNA to drive the patients immune system to attack and destroy tumors. “
Several other equities research analysts also recently weighed in on the company. Berenberg Bank decreased their price objective on Lucara Diamond from C$1.60 to C$1.50 in a report on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, April 1st. Finally, Cowen reissued a “buy” rating on shares of Alector in a report on Monday, May 13th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $20.50.
Gritstone Oncology (NASDAQ:GRTS) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.03. The business had revenue of $1.35 million during the quarter, compared to analyst estimates of $1.20 million. On average, research analysts forecast that Gritstone Oncology will post -2.39 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Gritstone Oncology in the fourth quarter valued at approximately $6,182,000. Citigroup Inc. purchased a new position in Gritstone Oncology in the fourth quarter valued at approximately $28,000. Northern Trust Corp purchased a new position in Gritstone Oncology in the fourth quarter valued at approximately $1,207,000. Geode Capital Management LLC purchased a new position in Gritstone Oncology in the fourth quarter valued at approximately $1,368,000. Finally, American International Group Inc. purchased a new position in Gritstone Oncology in the fourth quarter valued at approximately $70,000. 48.83% of the stock is owned by institutional investors and hedge funds.
About Gritstone Oncology
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
See Also: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.